Autolus Therapeutics (AUTL) News Today $1.22 -0.12 (-8.65%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Price T Rowe Associates Inc. MD Sells 902,261 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Price T Rowe Associates Inc. MD lowered its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,939,241 shares of the company's stock after selling 902,261 sharesMay 6 at 4:04 AM | marketbeat.comAutolus Therapeutics (AUTL) Projected to Post Quarterly Earnings on ThursdayAutolus Therapeutics (NASDAQ:AUTL) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-autolus-therapeutics-plc-stock/)May 3 at 7:29 AM | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Stake Boosted by Renaissance Technologies LLCRenaissance Technologies LLC increased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 618,942 sharApril 30, 2025 | marketbeat.comLegal & General Group Plc Buys 237,224 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Legal & General Group Plc grew its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 392.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 297,736 shares of the company's stock after buying an additional 237,22April 30, 2025 | marketbeat.comWalleye Capital LLC Trims Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)Walleye Capital LLC trimmed its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 92.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 75,940 shares of the company's stock after selling 986,453 shares during the period. Walleye Capital LLCApril 29, 2025 | marketbeat.comAutolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRAApril 27, 2025 | markets.businessinsider.comQ1 Earnings Estimate for AUTL Issued By William BlairAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for shares of Autolus Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.27) per shareApril 27, 2025 | marketbeat.comAutolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRAApril 26, 2025 | finance.yahoo.comUK approves Autolus leukemia therapy with conditionsApril 26, 2025 | investing.comAutolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)April 25, 2025 | globenewswire.comJPMorgan Chase & Co. Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)JPMorgan Chase & Co. lowered its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,071,533 shares of the company's stock after selling 213,175 shApril 25, 2025 | marketbeat.comEversept Partners LP Sells 307,663 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Eversept Partners LP decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 75.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,895 shares of the company's stock after selling 307,663April 24, 2025 | marketbeat.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | finance.yahoo.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | globenewswire.comAvoro Capital Advisors LLC Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Avoro Capital Advisors LLC cut its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 19.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,910,642 shares of the company's stock after selling 2,435,0April 23, 2025 | marketbeat.comAutolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 22, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Stock, Option ChainApril 18, 2025 | benzinga.comAutolus Therapeutics plc (NASDAQ:AUTL) Receives Average Recommendation of "Buy" from BrokeragesAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) has been assigned a consensus rating of "Buy" from the six analysts that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price amongApril 17, 2025 | marketbeat.comAutolus Therapeutics' (AUTL) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday.April 12, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP increased its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 4.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,345,680 shares of the company's stock after acquApril 7, 2025 | marketbeat.comTruist Financial Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday.April 2, 2025 | marketbeat.comAutolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comAutolus Therapeutics price target lowered to $10 from $11 at TruistApril 1, 2025 | markets.businessinsider.comAutolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025April 1, 2025 | globenewswire.comBIT Capital GmbH Buys 379,050 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)BIT Capital GmbH increased its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 147.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 636,979 shares of the company's stock after acquiring an additional 37March 28, 2025 | marketbeat.com191,429 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Bought by EntryPoint Capital LLCEntryPoint Capital LLC purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 191,429 shares of the company's stock, valued at approximately $450,000.March 27, 2025 | marketbeat.comEquities Analysts Offer Predictions for AUTL FY2028 EarningsAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Investment analysts at William Blair issued their FY2028 earnings per share estimates for shares of Autolus Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst M. Phipps forecasts that the companMarch 24, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Recommendation of "Buy" by BrokeragesShares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price oMarch 22, 2025 | marketbeat.comWells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock PriceWells Fargo & Company lowered their target price on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comTruist Financial Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)March 22, 2025 | markets.businessinsider.comWells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)March 21, 2025 | markets.businessinsider.comAutolus Therapeutics price target lowered to $6 from $8 at Wells FargoMarch 21, 2025 | markets.businessinsider.comAutolus Therapeutics sees cash runway to data in clincal trial of obe-celMarch 21, 2025 | markets.businessinsider.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up After Earnings BeatAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up on Better-Than-Expected EarningsMarch 21, 2025 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.12 EPSAutolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12.March 21, 2025 | marketbeat.comAutolus Therapeutics plc: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 20, 2025 | finanznachrichten.deAutolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call TranscriptMarch 20, 2025 | seekingalpha.comAutolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 20, 2025 | globenewswire.comAutolus Therapeutics FY 2024 Earnings PreviewMarch 19, 2025 | msn.comBank of New York Mellon Corp Reduces Stake in Autolus Therapeutics plc (NASDAQ:AUTL)Bank of New York Mellon Corp lessened its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,673,994 shares of the company's stock after selling 156,527March 19, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by TFG Asset Management GP LtdTFG Asset Management GP Ltd grew its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,250,000 shares of the company's stock after purchasing an additional 250,March 8, 2025 | marketbeat.com3,191,401 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Acquired by Candriam S.C.A.Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,191,401 shares of the company's stock, valued at approximately $7,50March 8, 2025 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for WeekMarch 7, 2025 | msn.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 7.4% - Here's What HappenedAutolus Therapeutics (NASDAQ:AUTL) Stock Price Up 7.4% - Still a Buy?March 6, 2025 | marketbeat.comAutolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025March 6, 2025 | globenewswire.comIs Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?March 6, 2025 | insidermonkey.comAutolus Therapeutics plc (NASDAQ:AUTL) is Syncona Portfolio Ltd's Largest PositionSyncona Portfolio Ltd reduced its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 10.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,640,720 shares of the company's stock after selling 1,913,9March 6, 2025 | marketbeat.comAutolus Therapeutics (AUTL) to Release Earnings on ThursdayAutolus Therapeutics (NASDAQ:AUTL) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comAutolus Therapeutics to Participate in Upcoming Investor ConferencesMarch 5, 2025 | globenewswire.com Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Media Mentions By Week AUTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼1.330.69▲Average Medical News Sentiment AUTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼43▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARS Pharmaceuticals News Today Dyne Therapeutics News Today 89bio News Today Ocular Therapeutix News Today Amphastar Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Wave Life Sciences News Today Iovance Biotherapeutics News Today Syndax Pharmaceuticals News Today Aurinia Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts